ANL Stock Overview
A clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Adlai Nortye Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.20 |
| 52 Week High | US$17.48 |
| 52 Week Low | US$1.85 |
| Beta | 0 |
| 1 Month Change | 1.38% |
| 3 Month Change | 6.53% |
| 1 Year Change | -74.33% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -85.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| ANL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.8% | 2.6% | 2.8% |
| 1Y | -74.3% | -3.3% | 24.6% |
Return vs Industry: ANL underperformed the US Biotechs industry which returned -3.8% over the past year.
Return vs Market: ANL underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| ANL volatility | |
|---|---|
| ANL Average Weekly Movement | 16.5% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ANL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ANL's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 127 | Carsten Lu | www.adlainortye.com |
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1.
Adlai Nortye Ltd. Fundamentals Summary
| ANL fundamental statistics | |
|---|---|
| Market cap | US$84.99m |
| Earnings (TTM) | -US$54.06m |
| Revenue (TTM) | US$5.00m |
16.2x
P/S Ratio-1.5x
P/E RatioIs ANL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANL income statement (TTM) | |
|---|---|
| Revenue | US$5.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$5.00m |
| Other Expenses | US$59.07m |
| Earnings | -US$54.06m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.47 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,081.30% |
| Debt/Equity Ratio | 72.9% |
How did ANL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 03:29 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Adlai Nortye Ltd. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Louise Chen | Cantor Fitzgerald & Co. |
| Joseph Pantginis | H.C. Wainwright & Co. |